Shanghai, China

Xiaoyan Zhou

USPTO Granted Patents = 4 

Average Co-Inventor Count = 6.7

ph-index = 2

Forward Citations = 19(Granted Patents)


Company Filing History:


Years Active: 2008-2019

Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Xiaoyan Zhou in Breast Cancer Research

Introduction

Xiaoyan Zhou is an esteemed inventor based in Shanghai, China, recognized for her significant contributions to the medical field, particularly in breast cancer research. With a total of four patents to her name, she has made remarkable strides in developing diagnostic and therapeutic methods aimed at improving patient outcomes.

Latest Patents

One of her notable inventions focuses on "Diagnostic and therapeutic methods and compositions involving PTEN and breast cancer." This invention highlights that patients with ErbB2-overexpressing cancers can be treated with an ErbB2 targeting agent. However, patient responsiveness varies. Zhou's innovative approach includes evaluating PTEN expression to predict a patient's responsiveness or resistance to therapies like trastuzumab. The findings suggest that low PTEN expression indicates a higher likelihood of poor response to this treatment, thereby informing better clinical decisions.

Career Highlights

Xiaoyan Zhou is currently affiliated with the University of Texas System, where she continues her impactful research. Her work is instrumental in bridging the gaps between basic research and clinical applications, enhancing the understanding of therapeutic strategies for breast cancer.

Collaborations

Throughout her career, Zhou has collaborated with distinguished colleagues, including Dihua Yu and Jun Yao. These partnerships not only foster innovation but also enable the sharing of diverse expertise in tackling complex medical challenges.

Conclusion

Xiaoyan Zhou's dedication to advancing breast cancer treatments through her patented innovations exemplifies the crucial role of inventors in the medical research landscape. Her work in evaluating PTEN expression will undoubtedly pave the way for more personalized and effective therapeutic strategies, highlighting the importance of precision medicine in oncology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…